Ginkgo Bioworks (DNA) Competitors $9.76 +0.16 (+1.64%) Closing price 03:59 PM EasternExtended Trading$9.74 -0.02 (-0.17%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. TWST, AMRX, CPRX, BHC, OGN, MIRM, XENE, IBRX, GMTX, and ARWRShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Twist Bioscience (TWST), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Twist Bioscience Amneal Pharmaceuticals Catalyst Pharmaceuticals Bausch Health Cos Organon & Co. Mirum Pharmaceuticals Xenon Pharmaceuticals ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation. Do institutionals and insiders believe in TWST or DNA? 78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer TWST or DNA? Twist Bioscience presently has a consensus target price of $50.40, indicating a potential upside of 40.59%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential downside of 12.88%. Given Twist Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Twist Bioscience is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is TWST or DNA more profitable? Twist Bioscience has a net margin of -54.98% compared to Ginkgo Bioworks' net margin of -198.84%. Twist Bioscience's return on equity of -33.48% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-54.98% -33.48% -25.34% Ginkgo Bioworks -198.84%-52.35%-27.14% Which has better earnings and valuation, TWST or DNA? Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M6.86-$208.73M-$3.25-11.03Ginkgo Bioworks$237.42M2.41-$547.03M-$9.16-1.07 Which has more risk & volatility, TWST or DNA? Twist Bioscience has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Does the media prefer TWST or DNA? In the previous week, Twist Bioscience had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 7 mentions for Twist Bioscience and 2 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.31 beat Ginkgo Bioworks' score of 0.15 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTwist Bioscience beats Ginkgo Bioworks on 13 of the 16 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$571.10M$2.93B$5.50B$20.79BDividend YieldN/A2.46%4.25%3.67%P/E Ratio-1.0720.3128.1027.50Price / Sales2.41261.57402.2885.54Price / CashN/A42.3835.5321.88Price / Book0.747.838.264.66Net Income-$547.03M-$55.11M$3.24B$994.58M7 Day Performance-9.43%2.18%0.50%-0.69%1 Month Performance13.65%12.98%7.99%5.41%1 Year PerformanceN/A1.98%28.68%9.18% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks0.7732 of 5 stars$9.76+1.6%$8.50-12.9%N/A$571.10M$237.42M-1.07640News CoverageTWSTTwist Bioscience4.2717 of 5 stars$35.59-6.8%$50.40+41.6%-37.5%$2.13B$312.97M-10.95990AMRXAmneal Pharmaceuticals2.8574 of 5 stars$8.41-0.1%$11.60+37.9%+8.7%$2.64B$2.79B-210.208,100CPRXCatalyst Pharmaceuticals4.8945 of 5 stars$20.95-2.4%$32.83+56.7%+24.7%$2.56B$491.73M13.3480Positive NewsBHCBausch Health Cos3.7148 of 5 stars$6.88-2.5%$7.42+7.8%-14.7%$2.55B$9.63B-62.5520,700OGNOrganon & Co.4.8563 of 5 stars$9.74-2.2%$18.00+84.8%-53.7%$2.53B$6.29B3.384,000MIRMMirum Pharmaceuticals3.118 of 5 stars$50.47+0.3%$65.50+29.8%+32.0%$2.50B$379.25M-31.35140XENEXenon Pharmaceuticals3.4725 of 5 stars$31.83-4.3%$54.82+72.2%-26.4%$2.44B$9.43M-9.85210Positive NewsIBRXImmunityBio2.1965 of 5 stars$2.72flat$12.25+350.4%-57.0%$2.40B$14.74M-4.69590GMTXGemini TherapeuticsN/A$54.75+3.0%N/A+14.3%$2.37BN/A-54.7530ARWRArrowhead Pharmaceuticals3.7554 of 5 stars$16.84+0.3%$43.71+159.6%-38.1%$2.33B$3.55M-12.03400News Coverage Related Companies and Tools Related Companies Twist Bioscience Competitors Amneal Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Bausch Health Cos Competitors Organon & Co. Competitors Mirum Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors ImmunityBio Competitors Gemini Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.